Consultant360 spoke with Keith Horvath, PhD, about his study, which indicated that technology-assisted HIV testing interventions could serve as a key strategy in reaching national and global targets for HIV...
In this podcast, Michael Reid, MD, from University of California, San Francisco, discusses the newest HIV-TB prevention therapies, the latest research on a new tuberculosis vaccine, and more.
PrEP has become more mainstream in the media, and the USPSTF recently recommended PrEP for all at-risk populations. Richard Chaisson, MD, shines light on these at-risk populations.
In this Q&A, Monica Gandhi, MD, MPH, discusses interventions to address the health care disparities that exist along the care continuum for certain patient populations who are at-risk for HIV...
In this video, Jeffrey Kwong, DNP, MPH, ANP-BC, discusses the under-utilization of HIV pre-exposure prophylaxis (PrEP) and the integral role primary care providers play in screening and identifying...
In this Editorial, Shobha Swaminathan, MD, writes about the shift from desperation and fear regarding HIV/AIDS in the 1980s to optimism and hope today.
In this video, Jeffrey Kwong, DNP, MPH, ANP-BC, provides a preview of his session "Preventing HIV: Strategies for Primary Care Clinicians" at our Practical Updates in Primary Care 2022 Virtual Series from...
In this podcast, Dr Landovitz discusses the findings from his recent trial, HPTN 083, which indicates that long-acting cabotegravir injected once every 8 weeks is superior to daily oral TDF/FTC in the...
In this podcast, Brooke Nichols, PhD, answers our questions about her team's novel and pragmatic metric to evaluate and compare pre-exposure prophylaxis program effectiveness using routine implementation...
Kathleen Ryan, PhD, answered our questions about her study, which indicated that rapid scale-up of PrEP was possible without the consequence of reduced HIV testing among Australian gay, bisexual, and other...
